Announcement • Jul 28
BioHarvest Sciences Inc. to Report Q2, 2026 Results on Aug 11, 2026 BioHarvest Sciences Inc. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on Aug 11, 2026 Announcement • Jul 15
BioHarvest Sciences Inc. Receives $1.4 Million Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis BioHarvest Sciences Inc. has received approval for a NIS 4.33 million (approximately USD 1.4 million) grant from the Israel Innovation Authority. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learning, computer vision and high-throughput digital sensing directly into BioHarvest’s biological development workflows, thereby accelerating its plant cell culture programs. BioHarvest's new approved research initiative focuses on moving plant cell culture from traditional empirical trial-and-error methods to a highly predictable, data-driven optimization framework. Specifically, by combining bioinformatics, chemo-informatics and artificial intelligence, the platform will systematically predict the success of plant cell propagation and dramatically maximize active metabolite yields. The program will accelerate the development of BioHarvest's advanced computational discovery engine. This platform integrates proprietary predictive machine learning models with real-time digital sensing to rapidly identify optimal pathways and maximize bioactive yields across diverse plant species. Supported by secure, domain-specific scientific knowledge bases, these new capabilities will streamline early-stage R&D, transforming how complex plant-based compounds are forecasted, monitored, and scaled. This marks the second grant BioHarvest has received from the Israel Innovation Authority this year. While the first grant was dedicated to scaling the manufacturing facility by integrating industrial automation and machine learning on the factory floor, this second grant is focused on transforming the early-stage R&D pipeline through predictive AI. Together, these two distinct yet highly complementary initiatives fuel a technological transformation across the company-bridging the gap between intelligent, data-driven laboratory discovery and high-volume, autonomous commercial production. The grant was provided by the Israel Innovation Authority in the form of a non-dilutive, zero-interest loan. Repayment is contingent upon the achievement of certain predefined commercial milestones and is expected to be made solely from future revenues generated by the funded project. No equity or equity-linked instruments were issued in connection with the grant. Reported Earnings • May 16
First quarter 2026 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2025) First quarter 2026 results: US$0.12 loss per share. Revenue: US$8.51m (up 8.2% from 1Q 2025). Net loss: US$2.64m (loss widened 13% from 1Q 2025). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Announcement • May 02
BioHarvest Sciences Inc. to Report Q1, 2026 Results on May 14, 2026 BioHarvest Sciences Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026 Breakeven Date Change • Apr 06
Forecast breakeven date pushed back to 2028 The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 40% per year to 2027. The company is expected to make a profit of US$15.1m in 2028. Average annual earnings growth of 58% is required to achieve expected profit on schedule. Reported Earnings • Apr 02
Full year 2025 earnings released: US$0.60 loss per share (vs US$0.80 loss in FY 2024) Full year 2025 results: US$0.60 loss per share (improved from US$0.80 loss in FY 2024). Revenue: US$34.5m (up 37% from FY 2024). Net loss: US$11.1m (loss narrowed 14% from FY 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Personal Products industry in Europe. Announcement • Mar 17
BioHarvest Sciences Inc. to Report Q4, 2025 Results on Mar 31, 2026 BioHarvest Sciences Inc. announced that they will report Q4, 2025 results After-Market on Mar 31, 2026 Announcement • Dec 05
BioHarvest Sciences Inc. Announces Launch of VINIA Blood Flow Hydration Product BioHarvest Sciences Inc. announced the U.S. launch of VINIA Blood Flow Hydration, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolyte Market. Better Hydration starts with Better Blood Flow. Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydation™? is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America. This product introduces a breakthrough concept to the rapidly growing hydration market: Hydration Powered by the Blood Flow benefits of VINIA'sPiceid Resveratrol, marking VINIA Blood Flow Hydrated™? as the world's first hydration formula with the power of VINIA's rapid absorption Piceid Resveratrol - designed to work synergistically to improve the body's circulation system and more efficiently deliver fluids and electrolytes where the body needs it most. VINIA Blood flow goes one step further and improves How electrolytes and nutrients get delivered. Containing the finest sources of natural electrolytes, the solution is formulated with premium sodium from sea salt, potassium from coconut water, and magnesium from marine ocean beds. This electrolyte solution is powered by VINIA's unique red grape polyphenol complex (23mg), including rapid absorption Piceid Res Veratrol (6mg), which has been clinically shown to significantly increase arterial dilation, improving blood flow. Better blood flow ensures more efficient transportation of electrolytes and fluids to body's organs, muscles, and cells, right where they're needed most. A New Era in Blood Flow-Driven Hydration Science. Products undergo rigorous testing using ISO 17025 accredited methods to provide the highest level of assurance for athletes. Every order is backed by BioHarvest's 90-Day "Feel It or It's Free" Guarantee, the industry's strongest consumer promise. Customers can use every stick for 90 days. If they do not love the taste or feel the VINIA®? difference, VINIA®? will refund the full purchase price and cover return shipping. No questions asked. The company has announced that VINIA Blood Flow Hydization is now available to all online consumers for purchase on VINIA.com and will be available on Amazon.com by the end of December. In addition to being available direct-to-consumer via the company's established e-commerce channels, VINIA Blood Flow hydration will also be distributed via select "point-of-sweat" outlets, to service active consumers looking for premium health solutions. Breakeven Date Change • Nov 15
Forecast breakeven date moved forward to 2026 The 3 analysts covering BioHarvest Sciences previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 15% to 2025. The company is expected to make a profit of US$1.08m in 2026. Average annual earnings growth of 74% is required to achieve expected profit on schedule. New Risk • Nov 12
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$4.2m). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Announcement • Nov 05
BioHarvest Sciences Inc. to Report Q3, 2025 Results on Nov 13, 2025 BioHarvest Sciences Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025 Announcement • Oct 06
BioHarvest Sciences Inc. announced that it has received CAD 0.553037 million in funding On October 6, 2025, BioHarvest Sciences Inc. closed the transaction. Announcement • Sep 24
BioHarvest Sciences Inc. announced that it has received CAD 5.1 million in funding BioHarvest Sciences Inc announced that it has completed a private placement and issued Convertible Notes for aggregate gross proceeds of CAD 5,100,000 on September 22, 2025. Breakeven Date Change • Sep 22
Forecast breakeven date pushed back to 2027 The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule. Breakeven Date Change • Aug 29
Forecast breakeven date pushed back to 2027 The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$6.47m in 2027. Average annual earnings growth of 69% is required to achieve expected profit on schedule. Reported Earnings • Aug 14
Second quarter 2025 earnings released: US$0.23 loss per share (vs US$0.042 loss in 2Q 2024) Second quarter 2025 results: US$0.23 loss per share (further deteriorated from US$0.042 loss in 2Q 2024). Revenue: US$8.52m (up 41% from 2Q 2024). Net loss: US$4.08m (loss widened 494% from 2Q 2024). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe. Breakeven Date Change • Aug 13 The 4 analysts covering BioHarvest Sciences previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 25% to 2025. The company is expected to make a profit of US$49.8k in 2026. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
Announcement • Aug 04
BioHarvest Sciences Inc. to Report Q2, 2025 Results on Aug 11, 2025 BioHarvest Sciences Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 11, 2025 Announcement • Jun 05
BioHarvest Sciences Inc. Announces the Launch of VINIA® DailyChews 2X Formula BioHarvest Sciences Inc. announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com. Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike. Reported Earnings • May 16
First quarter 2025 earnings released: US$0.14 loss per share (vs US$0.48 loss in 1Q 2024) First quarter 2025 results: US$0.14 loss per share (improved from US$0.48 loss in 1Q 2024). Revenue: US$7.86m (up 47% from 1Q 2024). Net loss: US$2.34m (loss narrowed 65% from 1Q 2024). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Europe. Announcement • May 02
BioHarvest Sciences Inc. to Report Q1, 2025 Results on May 15, 2025 BioHarvest Sciences Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025 Announcement • Mar 17
BioHarvest Sciences Inc. to Report Q4, 2024 Results on Mar 31, 2025 BioHarvest Sciences Inc. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025